[go: up one dir, main page]

MX2025010039A - Modulador dual de gen que codifica la enzima beta glucocerebrosidasa (gba1) y glucosilceramida sintasa (gcs) - Google Patents

Modulador dual de gen que codifica la enzima beta glucocerebrosidasa (gba1) y glucosilceramida sintasa (gcs)

Info

Publication number
MX2025010039A
MX2025010039A MX2025010039A MX2025010039A MX2025010039A MX 2025010039 A MX2025010039 A MX 2025010039A MX 2025010039 A MX2025010039 A MX 2025010039A MX 2025010039 A MX2025010039 A MX 2025010039A MX 2025010039 A MX2025010039 A MX 2025010039A
Authority
MX
Mexico
Prior art keywords
gba1
gcs
dual
dual modulator
prevention
Prior art date
Application number
MX2025010039A
Other languages
English (en)
Inventor
Takashi Kondo
Jun Takeuchi
Atsushi Kato
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MX2025010039A publication Critical patent/MX2025010039A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona un compuesto representado por la fórmula (I) o una sal farmacéuticamente aceptable del mismo, que es útil como un ingrediente farmacéutico que tiene una actividad moduladora dual de GBA1 y GCS en la prevención y/o el tratamiento de una enfermedad asociada con GBA1 y/o GCS, en donde todos los símbolos tienen el mismo significado que los símbolos descritos en la descripción. También se proporciona un fármaco que contiene, como un ingrediente activo, un compuesto que tiene una actividad moduladora dual de GBA1 y GCS en la prevención y/o el tratamiento de una enfermedad asociada con GBA1 y/o GCS.
MX2025010039A 2023-03-02 2025-08-25 Modulador dual de gen que codifica la enzima beta glucocerebrosidasa (gba1) y glucosilceramida sintasa (gcs) MX2025010039A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2023079232 2023-03-02
PCT/CN2024/078906 WO2024179491A1 (en) 2023-03-02 2024-02-28 Gba1 and gcs dual modulator

Publications (1)

Publication Number Publication Date
MX2025010039A true MX2025010039A (es) 2025-10-01

Family

ID=85781688

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025010039A MX2025010039A (es) 2023-03-02 2025-08-25 Modulador dual de gen que codifica la enzima beta glucocerebrosidasa (gba1) y glucosilceramida sintasa (gcs)

Country Status (8)

Country Link
EP (1) EP4673215A1 (es)
KR (1) KR20250152592A (es)
CN (1) CN120826391A (es)
AU (1) AU2024228129A1 (es)
IL (1) IL322900A (es)
MX (1) MX2025010039A (es)
TW (1) TW202502739A (es)
WO (1) WO2024179491A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1765379A4 (en) 2004-06-17 2009-05-27 Transform Pharmaceuticals Inc PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELEVANT USE METHOD
EP2323652A2 (en) * 2008-08-06 2011-05-25 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010029313A1 (en) * 2008-09-11 2010-03-18 Summit Corporation Plc. Antiinfective compounds
KR20160094848A (ko) 2013-05-02 2016-08-10 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 이미노당을 사용한 당지질 억제
EP3122726B1 (en) 2014-03-27 2018-08-29 Academisch Medisch Centrum N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase

Also Published As

Publication number Publication date
EP4673215A1 (en) 2026-01-07
WO2024179491A1 (en) 2024-09-06
TW202502739A (zh) 2025-01-16
IL322900A (en) 2025-10-01
KR20250152592A (ko) 2025-10-23
AU2024228129A1 (en) 2025-09-11
CN120826391A (zh) 2025-10-21

Similar Documents

Publication Publication Date Title
MX2025000772A (es) Compuesto heterociclico que actua sobre la proteina kras mutante g12d
PH12012502447A1 (en) Tetrahydrocarboline derivative
MX2025001619A (es) Inhibidor de pde4b y uso del mismo
WO2023078333A8 (zh) 一种取代的苯丙酸衍生物及其用途
PH12021553155A1 (en) Ep2 antagonist
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
MX2023011203A (es) Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular.
WO2023129956A3 (en) Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2025218831A3 (zh) 具有ptpn2/ptpn1抑制活性的噻二唑烷酮衍生物及其制备方法和应用
ZA202309001B (en) Abhd6 antagonist
JOP20220076A1 (ar) مثبطات عامل d المكمل عن طريق الفم
WO2022106902A3 (en) Benzenesulfonamide derivatives and uses thereof
BR112022009533A2 (pt) Composição farmacêutica para administração oral, e, método para preparar uma composição farmacêutica
MX2021009219A (es) Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria.
MX2025010039A (es) Modulador dual de gen que codifica la enzima beta glucocerebrosidasa (gba1) y glucosilceramida sintasa (gcs)
WO2020170032A3 (en) Method for treatment of rosacea in patients aged 65 years and older
MX2022012033A (es) Agente terapeutico para infeccion por coronavirus.
MX2023012483A (es) Formulaciones farmaceuticas transdermicas para el tratamiento del dolor cronico.
GEAP202516217A (en) Compounds and compositions as sppl2a inhibitors
EA202192483A1 (ru) Лекарственное средство и способ лечения или профилактики осложнений диабета с использованием этого лекарственного средства
MX2022009898A (es) Compuesto de dihidronaftiridinona y metodo de preparacion del mismo y uso medico del mismo.
WO2020190900A8 (en) Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof
MX2025003258A (es) Antagonista del dominio de alfa/beta-hidrolasa que contiene 6 (abhd6)
KR20230015320A (ko) 감염성 질환의 치료에서의 부실라민의 용도
CN113425720A8 (zh) 亚胺糖化合物在制备抗SARS-CoV-2病毒的药物中的用途